The demonstrated clinical benefit for cancer patients in response to anti-TGF-β and anti-inflammatory drugs suggests the prospect of further investigation of the “inflammation—tumor growth” relationship, including the induction of EMT in tumor cells by an inflammatory background. Here, TGFB1 is linked to neoplasm.